Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
By M. Dimopoulos, A. Oriol, H. Nahi, J. San-Miguel, N. Bahlis, S. Usmani, N. Rabin, R. Orlowski, M. Komarnicki, Kenshi Suzuki and 14 more. New England Journal of Medicine, 2016
1,308 citations recorded by the source corpus.
Subfields: Hematology, Oncology
View Paper: https://www.semanticscholar.org/paper/6b6fce3964ad0ebb31c36e1eb193838b909fefe0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Oncology
Citations in the corpus
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, background): “Recent advances in the treatment of relapsed multiple myeloma, including new active agents and results of major randomized trials are discussed below (Table 8).(66,68,69,71-73,75) 137-140 One important consideration is that the lenalidomide-containing regimens listed in Table 8 were tested mainly in”